STAR-II promising results in Ophthalmology Times

The six and 12-month results from the STAR-II trial on MINIjectTM have been reported in the latest issue of Ophthalmology Times.

Read more

iSTAR Medical 2021 roadmap at BioCapital Europe

CEO Michel Vanbrabant will present the company’s latest positive developments and an ambitious 2021 roadmap for iSTAR Medical at the Biocapital Europe meeting on 11 March.

Read more

MINIject STAR-II 12-month trial results at AGS

The 12-month results from the European STAR-II trial of iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM will be presented at the American Glaucoma Society (AGS) meeting.

Read more

MINIject in Ophthalmology Times Europe

An article in Ophthalmology Times Europe outlines how the suprachoroidal space promises to become a feasible route to effectively reduce intraocular pressure (IOP) in patients with glaucoma, thanks to iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM.
Read more

MINIject in Glaucoma Physician journal

In the latest issue of Glaucoma Physician, iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM features as a prominent solution to unlock the potential of the suprachoroidal space in glaucoma treatment.

Read more

MINIject’s 2020 results at EGS

The 2020 results from trials of minimally invasive glaucoma surgery (MIGS) device MINIjectTM will be presented at the upcoming European Glaucoma Society (EGS) annual meeting on 12-13 December. The consistently positive data showed outstanding results of intraocular pressure (IOP) and medication reduction in patients with open angle glaucoma, and a positive safety profile across trials.

The final two-year outcomes from the STAR-I clinical trial will be presented by Professor Doctor Philippe Denis, one of the trial investigators and Chair of the Department of Ophthalmology of Croix-Rousse University Hospital of Lyon, France. The one-year data from the European STAR-II trial will be presented by Professor Doctor Katrin Lorenz, Head of the Clinical Study Center at the Eye Clinic, Mainz University Medical Centre, Germany.

“In 2020, the STAR-I and STAR-II results brought very promising news in minimally invasive glaucoma surgery. They consistently confirmed that MINIject is a remarkably effective treatment option for patients, while maintaining very positive safety outcomes,” explained Professor Denis, who was also an investigator in the STAR-II trial. “These data bring promise that soon an optimal, effective and longer-lasting treatment for patients with glaucoma may be possible, while avoiding the risks associated with more invasive eye surgery,” he added.

Both data sets will be presented as on-demand video presentations during the congress and will be available to attendees for three months, and permanently to EGS members. To register: http://www.egs2020.org/node/14

iSTAR Medical’s “emerging technology” presented at IGC

MINIjectTM, iSTAR Medical’s minimally invasive glaucoma surgery (MIGS) device, has been presented as part of the ‘Emerging Technologies’ session at the prestigious 2020 virtual Interventional Glaucoma Congress (IGC) meeting. Dr Paul Singh, who presented iSTAR Medical’s technology, is a glaucoma specialist, President of The Eye Centers of Racine & Kenosha (Wisconsin, USA) and one of the implanting surgeons in MINIject trials.

“MINIject is able to maintain significant intraocular pressure reduction in the longer-term, with a reassuring safety profile, thanks to its innovative bio-integration and anti-inflammatory properties,” he explained. “The results seen so far in over 130 patients are certainly promising, particularly considering these results are achieved in a standalone procedure,” he added.

The IGC meeting is an invitation-only, think tank–style meeting for glaucoma specialists to exchange ideas on innovations and advanced practices for improved patient care. It is chaired by glaucoma specialists Doctors Ike Ahmed, Rick Lewis, and Arsham Sheybani.

Paul-Singh-IGC2020

iSTAR Medical wins BVA Award 2020!

iSTAR Medical has been awarded the 2020 BVA Venture Company of the Year at the BVA Award virtual ceremony today. The BVA Award is organised by the Belgian Venture Capital & Private Equity Association to reward and celebrate high-performing Belgian companies backed by private equity or venture capital funds.

“We are honoured and excited by the BVA award recognition. We have come a long way since MINIject was implanted in the first patient in 2017, thanks to our investors who believed in the technology and made it possible. MINIject has now been implanted in over 130 patients and its remarkable results are a game changer for patients with glaucoma,” stated Michel Vanbrabant, iSTAR Medical CEO.

iSTAR Medical is a medtech company pioneering minimally-invasive ophthalmic implants for powerful, safe and enduring treatment of patients with glaucoma. The company is headquartered in Wavre, Belgium.

iSTAR Medical’s CEO at OIS Glaucoma Innovation Showcase

OIS Glaucoma Showcase

CEO Michel Vanbrabant will illustrate the latest results for iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIject at the Glaucoma Innovation Showcase today. iSTAR Medical was selected as one of eight companies to showcase innovative glaucoma treatments to prospect investors at today’s meeting organised by the Ophthalmology Innovation Summit (OIS).

iSTAR Medical recently announced consistently positive safety and efficacy outcomes in over 130 patients implanted with MINIject, and presented subsets of these data at the European Society of Cataract and Refractive Surgery (ESCRS) meeting.

“MIGS are the most promising and fastest-growing therapy for glaucoma,” explained Vanbrabant, “we are truly excited about the latest, promising data in a larger patient population that tout MINIject as potentially best-in-class.”

OIS facilitates meaningful exchange of information to accelerate the development of novel therapies that address unmet clinical needs. It was founded by ophthalmologist/venture capitalist Emmett Cunningham of Blackstone Life Sciences and venture capitalist Bill Link of Versant Ventures/Flying L Partners.

Registration is free for the OIS glaucoma innovation showcase meeting: click here.

Meet iSTAR Medical’s new logo

Logo iSTAR Medical

Let us introduce you to iSTAR Medical’s new logo.

Our ‘eye’ embeds our purpose: improving the vision and lives of patients with glaucoma through powerful and safe ophthalmic implants with bio-integration.

The foundation of our technology is the proprietary, microporous, anti-fibrotic STAR® material, combined with intuitive access into the supraciliary space.

The unique outcomes: powerful enhancement of natural flow, bio-integration with surrounding tissue, and anti-inflammatory properties resulting in enduring results.